Sonelokimab (SLK) — Topline data
H2 2026
We expect to announce final topline results from the VELA-TEEN clinical trial in the second half of 2026.Source filing
MLTX biotech catalysts & pipeline
MOONLAKE IMMUNOTHERAPEUTICS · Data as of 2026-10-25
Upcoming catalysts
Sonelokimab (SLK) — Topline data
Q4 2026
• Q4 2026: Primary endpoint readout of the Phase 3 IZAR-2 trial in PsASource filing
Sonelokimab (SLK) — Filing acceptance
Nov 2026
End Nov. 2026: Expected to receive Prescription Drug User Fee Act (PDUFA) date allocation and decision on Priority ReviewSource filing
Sonelokimab (SLK) — Clinical data readout
H1 2027
The IZAR-1 trial remains blinded and will continue until Week 52 with MoonLake expecting the full readout in H1 2027 whereas the IZAR-2 trial (a trial in TNF-refractory patients) is expected to complete enrollment in Q3 2026Source filing
Sonelokimab (SLK) — Conference presentation
Sep 2026–Apr 2027
PsA/axial spondyloarthritis (axSpA): Expected to report results from the P-OLARIS trial at the end of 2026 or early 2027Source filing